Drug intelligence / Profile preview

Debio 1144

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral

Overview

**Debio 1144** is an investigational, orally available small molecule multikinase inhibitor licensed by Debiopharm from Ascepion Pharmaceuticals for oncology indications. It targets several tyrosine kinase oncogenes implicated in cancer growth, demonstrating strong efficacy in preclinical models of solid tumors with a large therapeutic index. Development focuses on cancers prevalent in China, supported by Debiopharm for further advancement in that market, though no clinical trial data or specific indications have advanced beyond preclinical stages.

Other names: Debio 1144Debio1144Debio-1144

Targets

MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on Debio 1144.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1144.

Explore the full profile